Summary
The response makes multiple drug-label-adjacent statements (patents/exclusivity/legal triggers) that are not supported by the FDA-approved prescribing information content provided in the prompt (clinical pharmacology/studies excerpts only). One claimed pharmacokinetics sentence is marked as unsupported due to insufficient verifiable label text.
Category Scores
Accurate Statements
PLEGRIDY did not accumulate in serum after multiple doses of 125 micrograms every 14 days.
Supported by FDA label quote in prompt: section 12.3 Pharmacokinetics includes the sentence.
Unsupported Statements
Plegridy is protected in the U.S. by one or more patents covering aspects of the drug, such as its composition, formulations, and/or manufacturing.
No FDA prescribing information text about patent protection or IP is provided in the prompt excerpts.
Exactly which U.S. patents apply to Plegridy (and their expiration dates) cannot be provided without the specific patent numbers or the Orange Book listing for Plegridy.
No prescribing information content provided addresses patent listing, Orange Book, or ability to identify patents.
The expiration of Plegridy’s U.S. patent protection depends on the specific U.S. patent(s) listed for Plegridy.
Prescribing information excerpts provided do not discuss patent expiration mechanics or listing.
The expiration of Plegridy’s U.S. patent protection depends on whether any exclusivity extends protection beyond patent expiry.
No prescribing information excerpts provided discuss regulatory exclusivity or patent/exclusivity interactions.
The expiration of Plegridy’s U.S. patent protection depends on any patent litigation, stays, or other legal events that delay generic/biosimilar entry.
No prescribing information excerpts provided discuss litigation or legal events affecting entry.
Generic drugs and biosimilars can face delayed market entry in the U.S. if a challenger contests a patent listed for the reference product.
No prescribing information excerpts provided address Hatch-Waxman/BPCIA processes or patent contestation mechanisms.
Generic drugs and biosimilars can face delayed market entry if courts impose a stay.
No prescribing information excerpts provided address court stays or related processes.
Whether such delayed market entry applies to Plegridy depends on current litigation status.
No prescribing information excerpts provided address Plegridy-specific litigation status.
Additional market-entry triggers and patent listing rules in the U.S. can prevent approval/launch of generics or biosimilars until relevant listed patents expire or are found not infringed/invalid.
No prescribing information excerpts provided discuss market-entry triggers, patent listing rules, infringement/invalidity findings.
Additional market-entry triggers and patent listing rules in the U.S. can prevent approval/launch until other legal milestones are reached.
No prescribing information excerpts provided discuss other legal milestones for market entry.
In the U.S., biosimilars or generics usually do not launch before the last patent expires.
No prescribing information excerpts provided address typical market-launch timing relative to patent expiry.
Contradictions
Important Omissions
No FDA-label evaluation is possible for many label domains (indications, dosage/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring, storage/handling) because the prompt did not provide those label sections, and the response content focused on patents/legal entry rather than label-directed safety/usage information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported patent/legal statements do not directly instruct dosing or clinical management. However, they do not align with FDA prescribing information and could mislead non-clinical decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are about U.S. patent/exclusivity and generic/biosimilar market-entry timing, which are not supported by the provided FDA prescribing information excerpts.
Suggested Improvement
Limit evaluation and responses to content explicitly supported by the provided FDA prescribing information text (e.g., clinical pharmacology/study results). Remove or clearly qualify non-label patent/legal statements as not derived from the prescribing information.